Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Veracyte (VCYT) Long-Term Debt Repayments (2016 - 2022)

Veracyte's Long-Term Debt Repayments history spans 4 years, with the latest figure at $1.2 million for Q4 2022.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $1.2 million in Q4 2022 year-over-year; TTM through Sep 2023 was $1.2 million, a 1162.77% increase, with the full-year FY2022 number at $1.3 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $1.2 million in Q4 2022 for Veracyte, up from -$3000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for VCYT hit a ceiling of $12.5 million in Q1 2019 and a floor of -$3000.0 in Q2 2022.